Mitiglinide Calcium/Metformin Hydrochloride

米格列奈钙/盐酸二甲双胍

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMitiglinide Calcium/Metformin Hydrochloride
Drug Alias NameMetformin Hydrochloride and Mitiglinide Calcium盐酸二甲双胍/米格列奈钙米格列奈钙盐酸二甲双胍metformin/Mitiglinide盐酸二甲双胍米格列奈钙 +[9] 
ClassificationSmall molecules
Mechanisms of ActionPotassium channel blockersProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsVoltage-gated potassium channel blockers
TargetsPotassium channelVoltage-gated potassium channelProtein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Metformin HydrochlorideMitiglinide
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKissei Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesElixir Pharmaceuticals IncKissei Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A